Macrophage migration inhibitory factor (MIF) plays a critical role in pathogenesis of ultraviolet-B (UVB)-induced nonmelanoma skin cancer (NMSC)

FASEB Journal

Volumn 23, Issue 3, 2009, Pages 720-730

  Martin, Jason ^a   Duncan, F Jason ^a   Reiser, Tracy ^b   Shin, Samuel ^a   Kusewitt, Donna F ^b   Oberyszyn, Tatiana ^b   Satoskar, Abhay R ^b,d   Varlbuskirk, Anne M ^a,b,c  

^a Department of Surgery ^*

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d TAKEDA PHARMACEUTICALS   (United States)

Author keywords

Angiogenesis; Edema; Tumorigenesis

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; DNA; MACROPHAGE MIGRATION INHIBITION FACTOR; MYELOPEROXIDASE; PROTEIN P53; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; EDEMA; ENZYME ACTIVITY; EPIDERMIS; FEMALE; INFLAMMATION; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NONMELANOMA SKIN CANCER; PATHOGENESIS; PRIORITY JOURNAL; RADIATION EXPOSURE; SKIN CANCER; ULTRAVIOLET B RADIATION; WILD TYPE;

ANIMALS; ANTIGENS, CD31; DOSE-RESPONSE RELATIONSHIP, RADIATION; EDEMA; FEMALE; GENE EXPRESSION REGULATION; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEOPLASMS, RADIATION-INDUCED; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS;

EID: 61449241792     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.08-119628     Document Type: Article

References (68)

1. Marks, R. (1995) The epidemiology of non-melanoma skin cancer: who, why and what can we do about it. J. Dermatol. 22, 853-857
2. Miller, D. L., and Weinstock, M. A. (1994) Nonmelanoma skin cancer in the United States: incidence. J. Am. Acad. Dermatol. 30, 774-778
3. Housman, T. S., Feldman, S. R., Williford, P. M., Fleischer, A. B., Jr., Goldman, N. D., Acostamadiedo, J. M., and Chen, G. J. (2003) Skin cancer is among the most costly of all cancers to treat for the Medicare population. J. Am. Acad. Dermatol. 48, 425-429
4. Chen, J. G., Fleischer, A. B., Jr., Smith, E. D., Kancler, C., Goldman, N. D., Williford, P. M., and Feldman, S. R. (2001) Cost of nonmelanoma skin cancer treatment in the United States. Dermatol. Surg. 27, 1035-1038
5. De Gruijl, F. R. (2000) Photocarcinogenesis: UVA vs UVB. Methods Enzymol. 319, 359-366
6. Gerber, B., Mathys, P., Moser, M., Bressoud, D., and Braun-Fahrlander, C. (2002) Ultraviolet emission spectra of sunbeds. Photochem. Photobiol. 76, 664-668
7. De Gruijl, F. R. (2002) Photocarcinogenesis: UVA vs. UVB radiation. Skin Pharmacol. Applied Skin Physiol. 15, 316-320
8. Dahle, J., Kvam, E., and Stokke, T. (2005) Bystander effects in UV-induced genomic instability: antioxidants inhibit delayed mutagenesis induced by ultraviolet A and B radiation. J. Car-cinog. 4, 11
9. De Haes, P., Garmyn, M., Verstuyf, A., De Clercq, P., Vande-walle, M., Degreef, H., Vantieghem, K., Bouillon, R., and Segaert, S. (2005) 1,25-Dihydroxyvitamin D3 and analogues protect primary human keratinocytes against UVB-induced DNA damage. J. Photochem. Photobiol. 78, 141-148
10. Besaratinia, A., Synold, T. W., Chen, H. H., Chang, C., Xi, B., Riggs, A. D., and Pfeifer, G. P. (2005) DNA lesions induced by UV A1 and B radiation in human cells: comparative analyses in the overall genome and in the p53 tumor suppressor gene. Proc. Natl. Acad. Sci. U.S.A. 102, 10058-10063
11. Budiyanto, A., Ueda, M., Ueda, T., and Ichihashi, M. (2002) Formation of cyclobutane pyrimidine dimers and 8-oxo-7,8-dihydro-2'-deoxyguanosine in mouse and organ-cultured human skin by irradiation with broadband or with narrowband UVB. Photochem. Photobiol. 76, 397-400
12. Cooke, M. S., Mistry, N., Ladapo, A., Herbert, K. E., and Lunec, J. (2000) Immunochemical quantitation of UV-induced oxidative and dimeric DNAdamage to human keratinocytes. Free Rad. Res. 33, 369-381
13. Van der Kemp, P. A., Blais, J. C., Bazin, M., Boiteux, S., and Santus, R. (2002) Ultraviolet-B-induced inactivation of human OGG1, the repair enzyme for removal of 8-oxoguanine in DNA. Photochem. Photobiol. 76, 640-648
14. Berton, T. R., Mitchell, D. L., Guo, R., and Johnson, D. G. (2005) Regulation of epidermal apoptosis and DNA repair by E2F1 in response to ultraviolet B radiation. Oncogene 24, 2449-2460
15. Cadet, J., Sage, E., and Douki, T. (2005) Ultraviolet radiation-mediated damage to cellular DNA. Mutat. Res. 571, 3-17
16. Ehrhart, J. C., Gosselet, F. P., Culerrier, R. M., and Sarasin, A. (2003) UVB-induced mutations in human key gatekeeper genes governing signalling pathways and consequences for skin tumourigenesis. Photochem. Photobiol. Sci. 2, 825-834
17. Halliday, G. M. (2005) Inflammation, gene mutation and photoimmunosuppression in response to UVR-induced oxidative damage contributes to photocarcinogenesis. Mutat. Res. 571, 107-120
18. Hawk, J. L., Murphy, G. M., and Holden, C. A. (1988) The presence of neutrophils in human cutaneous ultraviolet-B inflammation. Brit. J. Dermatol. 118, 27-30
19. Sams, R. L., 2nd, Couch, L. H., Miller, B. J., Okerberg, C. V., Warbritton, A. R., Wamer, W. G., Beer, J. Z., and Howard, P. C. (2002) Effects of alpha- and beta-hydroxy acids on the edemal response induced in female SKH-1 mice by simulated solar light. Toxicol. Applied Pharmacol. 184, 136-143
20. Wilgus, T. A., Ross, M. S., Parrett, M. L., and Oberyszyn, T. M. (2000) Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation. Prostag. Other Lipid Media 62, 367-384
21. Piskin, G., Bos, J. D., and Teunissen, M. B. (2005) Neutrophils infiltrating ultraviolet B-irradiated normal human skin display high IL-10 expression. Arch. Dermatol. Res. 296, 339-342
22. Savage, J. E., Theron, A. J., and Anderson, R. (1993) Activation of neutrophil membrane-associated oxidative metabolism by ultraviolet radiation. J. Investig. Dermatol. 101, 532-536
23. Brash, D. E., Ziegler, A., Jonason, A. S., Simon, J. A., Kunala, S., and Leffell, D. J. (1996) Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J. Investig. Dermatol. Symp. Proc. 1, 136-142
24. De Gruijl, F. R. (2002) p53 mutations as a marker ofskin cancer risk: comparison of UVA and UVB effects. Exp. Dermatol. 11 (Suppl. 1), 37-39
25. Chuang, T. Y., and Brashear, R. (1999) Risk factors of non-melanoma skin cancer in United States veterans patients: a pilot study and review of literature. J. Eur. Acad. Dermatol. Venereol. 12, 126-132
26. Osterlind, A. (1991) Etiology and epidemiology of melanoma and skin neoplasms. Curr. Opin. Oncol. 3, 355-359
27. Strom, S. S., and Yamamura, Y. (1997) Epidemiology of non-melanoma skin cancer. Clin. Plast. Surg. 24, 627-636
28. Bucala, R., and Donnelly, S. C. (2007) Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity 26, 281-285
29. Javeed, A., Zhao, Y., and Zhao, Y. (2008) Macrophage-migration inhibitory factor: role in inflammatory diseases and graft rejection. Inflamm. Res. 57, 45-50
30. Bando, H., Matsumoto, G., Bando, M., Muta, M., Ogawa, T., Funata, N., Nishihira, J., Koike, M., and Toi, M. (2002) Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn. J. Cancer Res. 93, 389-396
31. Koong, A. C., Denko, N. C., Hudson, K. M., Schindler, C., Swiersz, L., Koch, C., Evans, S., Ibrahim, H., Le, Q. T., Terris, D. J., and Giaccia, A. J. (2000) Candidate genes for the hypoxic tumor phenotype. Cancer Res. 60, 883-887
32. Shimizu, T., Abe, R., Nakamura, H., Ohkawara, A., Suzuki, M., and Nishihira, J. (1999) High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem. Biophys. Res. Commun. 264, 751-758
33. Meyer-Siegler, K., Fattor, R. A., and Hudson, P. B. (1998) Expression of macrophage migration inhibitory factor in the human prostate. Diagn. Mol. Pathol 7, 44-50
34. Bozza, M., Satoskar, A. R., Lin, G., Lu, B., Humbles, A. A., Gerard, C., and David, J. R. (1999) Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J. Exp. Med. 189, 341-346
35. Thomas-Ahner, J. M., Wulff, B. C., Tober, K. L., Kusewitt, D. F., Riggenbach, J. A., and Oberyszyn, T. M. (2007) Gender differences in UVB-induced skin carcinogenesis, inflammation, and DNA damage. Cancer Res. 67, 3468-3474
36. Bolontrade, M. F., Stern, M. C., Binder, R. L., Zenklusen, J. C., Gimenez-Conti, I. B., and Conti, C. J. (1998) Angiogenesis is an early event in the development of chemically induced skin tumors. Carcinogenesis 19, 2107-2113
37. Hatton, J. L., Parent, A., Tober, K. L., Hoppes, T., Wulff, B. C., Duncan, F. J., Kusewitt, D. F., VanBuskirk, A. M., and Oberyszyn, T. M. (2007) Depletion of CD4+ cells exacerbates the cutaneous response to acute and chronic UVB exposure. J. Investig. Dermatol. 127, 1507-1515
38. Wulff, B. C., Schick, J. S., Thomas-Ahner, J. M., Kusewitt, D. F., Yarosh, D. B., and Oberyszyn, T. M. (2007) Topical treatment with OGG1 enzyme affects UVB-induced skin carcinogenesis. Photochem. Photobiol. 84, 317-321
39. Chesney, J., Metz, C., Bacher, M., Peng, T., Meinhardt, A., and Bucala, R. (1999) An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol. Med. 5, 181-191
40. Ren, Y., Tsui, H. T., Poon, R. T., Ng, I. O., Li, Z., Chen, Y., Jiang, G., Lau, C., Yu, W. C., Bacher, M., and Fan, S. T. (2003) Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int. J. Cancer 107, 22-29
41. White, E. S., Strom, S. R., Wys, N. L., and Arenberg, D. A. (2001) Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. J. Immunol. 166, 7549-7555
42. DeLisser, H. M., Newman, P. J., and Albelda, S. M. (1994) Molecular and functional aspects of PECAM-1/CD31. Immunol. Today 15, 490-495
43. Lundberg, C., and Arfors, K. E. (1983) Polymorphonuclear leukocyte accumulation in inflammatory dermal sites as measured by 51Cr-labeled cells and myeloperoxidase. Inflammation 7, 247-255
44. Jung, H., Seong, H. A., and Ha, H. (2008) Critical role of cysteine residue 81 of macrophage migration inhibitory factor (MIF) in MIF-induced inhibition of p53 activity. J. Biol. Chem. 283, 20383-20396
45. Mitchell, R. A., Liao, H., Chesney, J., Fingerle-Rowson, G., Baugh, J., David, J., and Bucala, R. (2002) Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl. Acad. Sci. U.S.A. 99, 345-350
46. Hudson, J. D., Shoaibi, M. A., Maestro, R., Carnero, A., Hannon, G. J., and Beach, D. H. (1999) A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 190, 1375-1382
47. Ferrara, N. (2001) Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol 280, C1358-C1366
48. Calandra, T., Bernhagen, J., Metz, C. N., Spiegel, L. A., Bacher, M., Donnelly, T., Cerami, A., and Bucala, R. (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377, 68-71
49. Daun, J. M., and Cannon, J. G. (2000) Macrophage migration inhibitory factor antagonizes hydrocortisone-induced increases in cytosolic IkappaBalpha. Am. J. Physiol. 279, R1043-1049
50. Roger, T., Chanson, A. L., Knaup-Reymond, M., and Calandra, T. (2005) Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-in-duced expression of mitogen-activated protein kinase phospha-tase-1. Eur. J. Immunol. 35, 3405-3413
51. Bacher, M., Metz, C. N., Calandra, T., Mayer, K., Chesney, J., Lohoff, M., Gemsa, D., Donnelly, T., and Bucala, R. (1996) An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc. Natl. Acad. Sci. U.S.A. 93, 7849-7854
52. Calandra, T., and Roger, T. (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat. Rev. 3, 791-800
53. Takahashi, N., Nishihira, J., Sato, Y., Kondo, M., Ogawa, H., Ohshima, T., Une, Y., and Todo, S. (1998) Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol. Med. 4, 707-714
54. Winner, M., Koong, A. C., Rendon, B. E., Zundel, W., and Mitchell, R. A. (2007) Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Res. 67, 186-193
55. Kleemann, R., Hausser, A., Geiger, G., Mischke, R., Burger-Kentischer, A., Flieger, O., Johannes, F. J., Roger, T., Calandra, T., Kapurniotu, A., Grell, M., Finkelmeier, D., Brunner, H., and Bernhagen, J. (2000) Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408, 211-216
56. Wilgus, T. A., Koki, A. T., Zweifel, B. S., Kusewitt, D. F., Rubal, P. A., and Oberyszyn, T. M. (2003) Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment. Mol. Carcinog. 38, 49-58
57. Lan, H. Y., Bacher, M., Yang, N., Mu, W., Nikolic-Paterson, D. J., Metz, C., Meinhardt, A., Bucala, R., and Atkins, R. C. (1997) The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J. Exp. Med. 185, 1455-1465
58. Zhang, W., Yue, B., Wang, G. Q., and Lu, S. L. (2002) Serum and ascites levels of macrophage migration inhibitory factor, TNF-alpha and IL-6 in patients with chronic virus hepatitis B and hepatitis cirrhosis. Hepatobiliary Pancreat. Dis. Int. 1, 577-580
59. Donnelly, S. C., Haslett, C., Reid, P. T., Grant, I. S., Wallace, W. A., Metz, C. N., Bruce, L. J., and Bucala, R. (1997) Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat. Med. 3, 320-323
60. Kobayashi, S., Nishihira, J., Watanabe, S., and Todo, S. (1999) Prevention of lethal acute hepatic failure by antimacrophage migration inhibitory factor antibody in mice treated with bacille Calmette-Guerin and lipopolysaccharide. Hepatology 29, 1752-1759
61. Sasaki, S., Nishihira, J., Ishibashi, T., Yamasaki, Y., Obikane, K., Echigoya, M., Sado, Y., Ninomiya, Y., and Kobayashi, K (2004) Transgene of MIF induces podocyte injury and progressive mesangial sclerosis in the mouse kidney. Kidney Int. 65, 469-481
62. Hoi, A. Y., Hickey, M. J., Hall, P., Yamana, J., O'Sullivan, K M., Santos, L. L., James, W. G., Kitching, A. R., and Morand, E. F. (2006) Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J. Immunol. 177, 5687-5696
63. Mizue, Y., Ghani, S., Leng, L., McDonald, C., Kong, P., Baugh, J., Lane, S. J., Craft, J., Nishihira, J., Donnelly, S. C., Zhu, Z., and Bucala, R. (2005) Role for macrophage migration inhibitory factor in asthma. Proc. Natl. Acad. Sci. U.S.A. 102, 14410-14415
64. Bando, H., Toi, M., Kitada, K., and Koike, M. (2003) Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231. Biomed. Pharmacother. 57, 333-340
65. Morand, E. F., and Leech, M. (2005) Macrophage migration inhibitory factor in rheumatoid arthritis. Front. Biosci. 10, 12-22
66. Baugh, J. A., Gantier, M., Li, L., Byrne, A., Buckley, A., and Donnelly, S. C. (2006) Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1. Biochem. Biophys. Res. Commun. 347, 895-903
67. Donn, R. P., Shelly, E., Ollier, W. E., and Thomson, W. (2001) A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 44, 1782-1785
68. Baugh, J. A., Chitnis, S., Donnelly, S. C., Monteiro, J., Lin, X., Plant, B. J., Wolfe, F., Gregersen, P. K., and Bucala, R. (2002) A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun. 3, 170-176